Analysis of Volatile Organic Compounds — CPB 0717 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0717 covering volatile organic compound (VOC) analysis, effective November 27, 2025. Every indication on the list is experimental — meaning no reimbursement, and claims will deny.

Aetna's volatile organic compounds coverage policy under CPB 0717 in the Aetna system now formally classifies VOC analysis as experimental, investigational, or unproven across more than 30 clinical indications. The list spans cancer detection, infectious disease diagnosis, chronic disease monitoring, and pediatric screening. If your lab or ordering practice submits claims for VOC analysis against any of the ICD-10 codes in this bulletin — including the broad C00.0–C96.9 malignant neoplasm range and A15.0–A19.9 tuberculosis codes — expect a claim denial. There are no covered indications in this policy.

Quick-Reference Table

Aetna Volatile Organic Compound Analysis Coverage Criteria and Medical Necessity Requirements 2025

The short answer on Aetna VOC analysis coverage: there are no covered indications. Aetna does not recognize VOC analysis as meeting medical necessity criteria for any of the conditions listed in CPB 0717.

This is a blanket exclusion policy, not a narrow carve-out. Aetna's position is that clinical effectiveness has not been established for VOC analysis across every indication addressed in the bulletin. That's a sweeping statement covering oncology, pulmonology, infectious disease, gastroenterology, nephrology, and neurology in one policy document.

There are no prior authorization pathways listed in CPB 0717 that would allow coverage under exceptional circumstances. Prior auth doesn't help you here — the procedure itself is non-covered. That distinction matters for your billing team's workflow. Don't waste time on prior auth requests for VOC analysis billed to Aetna members.

From a reimbursement standpoint, any claim submitted with a VOC analysis procedure code linked to these ICD-10 diagnosis codes will fail on medical necessity grounds. The coverage policy is unambiguous on this point.

Aetna VOC Analysis Exclusions and Non-Covered Indications

This is the core of CPB 0717, and the list is long. Aetna considers VOC analysis experimental, investigational, or unproven for every indication below.

The breadth here is striking. This isn't a policy that covers VOC analysis for condition X but not condition Y. Aetna's position is that the entire technology lacks established clinical effectiveness. That's the same posture Aetna has taken on several emerging diagnostic technologies — draw a hard line until peer-reviewed evidence meets their clinical review bar.

The full list of non-covered indications includes:

That last item — hemodialysis monitoring — pulls nephrology into scope. If your dialysis center or nephrology group has been exploring VOC-based monitoring tools, this policy closes that door with Aetna patients.

The autism spectrum disorder and juvenile idiopathic arthritis inclusions are worth flagging for pediatric practices. VOC-based diagnostic tools have attracted research interest in pediatric populations. Aetna's position is clear: not covered, regardless of the population.

Coverage Indications at a Glance

No indication in CPB 0717 carries a "Covered" status. Every row in this table is a denial waiting to happen.

Aetna VOC Analysis Billing Guidelines and Action Items 2025

This policy has a November 27, 2025 effective date. If your team has submitted VOC analysis claims to Aetna after that date, pull those claims now.

If you're running a clinical lab and VOC analysis represents a meaningful revenue line, talk to your compliance officer before the end of 2025. This policy, combined with similar experimental designations at other major payers, suggests the coverage environment for VOC-based diagnostics won't improve in the near term without significant published clinical trial data.

CPT, HCPCS, and ICD-10 Codes for Volatile Organic Compound Analysis Under CPB 0717

CPB 0717 does not list specific CPT or HCPCS codes in the policy data. The volatile organic compounds billing exposure here is driven entirely by the ICD-10 diagnosis code side of the claim. The ICD-10 codes listed in the policy define the diagnostic contexts where Aetna applies this experimental designation.

Key ICD-10-CM Diagnosis Codes

The policy includes 402 ICD-10-CM codes. The ranges and specific codes listed in the policy data are below. These are the codes Aetna ties to the experimental determination in CPB 0717.

The full policy lists 402 ICD-10-CM codes. The remaining 322 codes not reproduced here span additional carcinoma in situ of breast subcategories and extend into other diagnosis categories. Review the complete CPB 0717 policy at Aetna's clinical policy bulletins for the full code list.